Remove 2019 Remove Clinical Trials Remove Education Remove Safety
article thumbnail

‘Too costly, not enough evidence it works’, says UK in blow to cannabis campaigners

Cannabis Law Report

However, health professionals have been reluctant to prescribe cannabis-based medicines in the UK because of the lack of clinical trial evidence of its benefits and safety. This would answer questions about safety and efficacy, they said. The final guideline is expected to be published in November 2019.

article thumbnail

Do you trust your doctor about cannabis?

The Cannigma

Medical societies are slowly providing more CME (continuing medical education) to doctors on cannabis, however, that educational content tends to be slanted toward risk mitigation. Fortunately, there is a slowly growing community of cannabis physicians who are learning through trial and error and from one another.

Education 101
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harvard Is Launching America’s First Psychedelics Law and Policy Center

SpeedWeed

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release. Several prestigious American universities have launched their own psychedelics centers in the past decade.

Policy 52
article thumbnail

Meredith Fisher-Corn, MD…….”Are You Able to Answer Your Patients’ Medical Marijuana Questions”

TheAnswerPage

As the Editor-in-Chief of the medical education website called TheAnswerPage.com for nearly two decades, I have assessed multiple educational gaps in the healthcare community. Thus, an educational gap developed, creating a less than ideal situation for medical marijuana patients. So, why did this educational gap develop?

article thumbnail

New Study: Demographic and policy-based differences in behaviors and attitudes towards driving after marijuana use: an analysis of the 2013–2017 Traffic Safety Culture Index

Cannabis Law Report

The Traffic Safety Culture Index is an annual survey with national scope and multiple measures relevant to driving after marijuana use. Because THC presence is an imperfect proxy for impairment [ 10 ], driving data may be limited in clarifying what traffic safety risks, if any, are associated with permissive marijuana policies.

Policy 59
article thumbnail

Skin Cancer Drugs Global Market Report 2021: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma – ResearchAndMarkets.com

Cannabis Law Report

In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for safety and benefit of the customer, in the European Union Region. Examples of skin cancer drug include 5-FU, Aldara and Efudex.

article thumbnail

Cannabis Industry Leaders Speak With CLR on Current Delta 8 Issues In The Industry

Cannabis Law Report

Titus then went on to earn his PhD from Open International University, an educational organization affiliated with the World Health Organization. Dr. Titus holds a Fellowship with the American Academy of Pain Management and clinical association with the American Association of Integrative Medicine. for CS First Boston Corp.